WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) will announce today at the 25th Annual JPMorgan Healthcare Conference positive preliminary results from a Phase IIa placebo-controlled trial designed to evaluate the anti-viral effects and safety of INCB9471, Incyte’s lead CCR5 antagonist that is being developed as a once-a-day oral treatment for patients with human immunodeficiency virus (HIV) infections. In the first seven treated patients the compound was well tolerated over the 14-day trial period with a 1.7 log10 viral load drop at day 14. Consistent with the compound’s long half-life of 60 hours, viral replication continued to be suppressed after the last dose with a nadir in viral load reduction of 2.1 log10 seen at day 20.
